Experimental Research

**Helicobacter pylori** co-infection with Epstein-Barr virus and the risk of developing gastric adenocarcinoma at an early age: Observational study of infectious agents and cancer

Fatima Ezzahra Rihane\(^a,b\), Driss Erguibi\(^c\), Othmane Elyamine\(^c\), Berjas Abumsimir\(^b\), Moulay Mustapha Ennaji\(^b,c\), Farid Chehab\(^c\)

\(^a\) Laboratory of Genetic and Molecular Pathology, Faculty of Medicine & Pharmacy Casablanca. University Hassan II of Casablanca, 20360, Morocco
\(^b\) Laboratory of Virology, Microbiology, Quality, Biotechnologies/ Ecotoxicology and Biodiversity, Faculty of Sciences & Technologies Mohammedia. University Hassan II of Casablanca, 20650, Morocco
\(^c\) Service of Digestive Cancers Surgery and Liver Transplant, Department of Surgery. Ibn Rochd University Hospital Center, Faculty of Medicine

**A B S T R A C T**

Background: Gastric cancer (GC) is one of the leading causes of morbidity and mortality worldwide. The onset and progression of gastric cancer are attributed to numerous triggers, these triggers may be infection of the gastric epithelium by *Helicobacter pylori* (*H. pylori*), or by Epstein-Barr virus (EBV). Both agents can establish a lifelong persistent infection in the host, leading to chronic inflammation, which also contributes to cancer development. Objective: The objective of this study is to present the status of co-infection with *H. pylori* and EBV and the risk of developing adenocarcinoma at an early age in the population of Grand Casablanca.

Methods: In this study, 100 gastric tissue samples from patients with gastric cancer were examined for detection of *H. pylori* and EBV in tumor tissue using PCR techniques, and the clinical relevance was statistically analyzed.

Results: Results revealed an individual Epstein-Barr virus (EBV) infection observed in (40 %) of gastric carcinoma cases. Furthermore, the frequency of EBV infection was significantly different with intestinal and diffuse gastric cancer types [15 % vs. 85 %; \(<0.05\)]. The prevalence of individual *H. pylori* infections was 34 %, while the frequency of co-infection was 16 %. Moreover, no significant association was found between co-infection and sex, tumor grade, stage, and lymph node metastasis, but there was a significant association between co-infection and the age of GC patients.

Conclusion: Thus understanding the status of co-infection could clarify the process of gastric carcinogenesis, and application of this knowledge for clinical purposes could facilitate diagnosis, risk management, and prevention.

**1. Introduction**

Gastric cancer (GC), or stomach cancer, is the most prevalent malignancy in the world [1]. Despite the reduction in frequency and mortality rates in recent decades, it is still the fifth most common cancer and the third leading cause of cancer death worldwide, with an estimate of 1,033,701 new cases and 782,685 deaths related to GC recorded in 2018 [2].

GC is cancer with a recognized infectious etiology, involving viruses and bacteria. Recently, several studies have been carried out to understand the role of pathogens that infect the human stomach, especially *Helicobacter pylori* (*H. pylori*), which is considered the most common cause of gastric carcinogenesis, it is classified as a class 1 carcinogen by the World Health Organization [3–5]. And there is also the main risk factor that is the Epstein-Barr Virus (EBV), involved in gastric carcinogenesis [6]. Both pathogens are usually acquired early in life, with about 50 % of the world’s adult population infected with *H. pylori* and 90 % with EBV [7,8].

Carcinogenic pathogens are classified as acting directly or indirectly according to their mechanisms of transformation [9]. Although *H. pylori*
infectivity on epithelial cells [17]. EBV can induce gastric epithelial cell in vitro studies suggest that EBV-infected B cells generate a high level of superficial epithelium of the stomach through B cells carrying reac
[13/19], and each subject signed informed committee of the Faculty of Medicine and Pharmacy of Casablanca, Morocco with EBV and the risk of developing adenocarcinoma at an early age, as [19, 20]. reinforces the causal relationship between EBV and gastric carcinogenesis [12–14]. EBV infection has been associated with several types of B-cell lymphomas and upper gastrointestinal carcinomas, and it can infect the superficial epithelium of the stomach through B cells carrying reactivated EBV, which can trigger carcinogenesis [15, 16]. Results from in vitro studies suggest that EBV-infected B cells generate a high level of infectivity on epithelial cells [17]. EBV can induce gastric epithelial cell death or persist as a latent infection and promote cancer progression [10, 11]. On the other hand, EBV is considered a direct transforming pathogen through the expression of its own -malignant transformation [10, 11].

Finding suggests that all these cells originated from the same infected progenitor cell, and the viral monoclonality in EBV-positive GC reinforces the causal relationship between EBV and gastric carcinogenesis [19, 20]. The present study aimed to present the status of H. pylori co-infection with EBV and the risk of developing adenocarcinoma at an early age, as well as the evaluation of the clinicopathological features associated with the presence of infectious agents.

2. Materials and methods

2.1. Patients and samples

A total of 100 gastric tissue samples from patients who underwent gastric resection in the department of surgery of Ibn Rochd University Hospital Center, Casablanca, were included in this study. All clinical and pathological parameters were recorded by the physicians in the medical record registry the department of surgery of Ibn Rochd University Hospital Center, Casablanca.

The study was approved by the Biomedical Research Ethics Committee of the Faculty of Medicine and Pharmacy of Casablanca, Morocco (Reference number: No 13/19), and each subject signed informed consent.

2.2. DNA extraction for the detection of Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV)

Tissue samples were immediately frozen and stored at −80 °C until use. DNA was extracted from the tissues using the Pure link Invitrogen® Genomic DNA mini kit, Thermo Fisher USA, according to the manufacturer’s instructions. The quality and quantity of the DNA obtained were evaluated using NanoDrop 2000 (Technologies, Wilmington, DE, USA).

2.3. Detection of H. pylori and EBV

H. pylori were detected in biopsies by PCR using glmM primers [21]. And the cagA status was checked using the primers as described previously [22]. EBV was detected using nested PCR. Primers for this virus were determined as previously described [23]. Briefly, PCR reaction was carried out in a 25 μl reaction mixture containing genomic DNA (8 ng), 2 × Taq PCR master mix kit Qiagen USA, 10 μmol forward and reverse primers. PCR amplification was performed using a PerkinElmer 2400 GeneAmp PCR System 2400 Thermal Cycler®, CA, USA. Using the primers indicated in Supplementary Table S1. Cycling conditions were as follows: denaturation at 94 °C for 3 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at the specific temperature for 1 min, extension at 72 °C for 1 min, and the reaction was finished with a 10 min extension at 72 °C. PCR products were size-fractionated by gel electrophoresis for 1.5 h at 70 V on 2 % agarose.

2.4. Statistical analysis

Statistical analysis was performed using SPSS 23.0 statistical software (SPSS, Inc., Chicago, IL, USA). The correlation between the different disease parameters was analyzed by the Student’s t-test, the Chi-square test, and the Fisher exact test. The difference was considered significant when the p-value was less than 0.05.

The current paper has been formulated and reported following the STROCSS criteria [24].

3. Results

3.1. Clinicopathological characteristics

Table 1 represents the clinicopathological characteristics of the recruited patients. Using the median age; which is 58 years (range, 36–72 years); all GC patients were divided into two age groups: patients aged 58 years or older and patients younger than 58 years.

Based on Lauren’s classification, the most widely used system for gastric adenocarcinomas, there are two main types of gastric tumors: the diffuse type, which has a worse prognosis and is characterized by invasive growth and the absence of precancerous lesions, and the second Table 1

| Patients’ clinicopathological characteristics. | % |
|-----------------------------------------------|---|
| **Age**                                       |   |
| <58 years                                     | 50 |
| ≥58 years                                     | 50 |
| **Gender**                                    |   |
| Male                                          | 56 |
| Female                                        | 44 |
| **Lauren’s classification**                   |   |
| Intestinal type                               | 42 |
| Diffuse type                                  | 58 |
| **Lymph node metastasis**                     |   |
| Negative                                      | 28 |
| Positive                                      | 72 |
| **Stage**                                     |   |
| Low (I and II)                                | 30 |
| High (III and IV)                             | 70 |

*The mean and median to 58. Therefore, we set this age as a dividing line between two age groups: <58 and ≥58.

Fig. 1. Association between the age of gastric cancer patients and their infection status.
one, which is intestinal type, whose development depends on environmental factors and is associated with precancerous lesions, especially chronic and atrophic gastritis, metaplasia and dysplasia [25–27]. According to this classification, 58% of the samples were of the diffuse type and the remaining 42% of the intestinal type. As shown in Table 1, according to the TNM classification [28], most samples were high stage.

### 3.2. H. pylori and EBV detection

Overall, \( H. pylori \) DNA was found in 34% of GC samples, and the cagA gene was detected in all 34H. pylori-positive tissues. The EBV DNA was detected in 40%, and the co-infection was detected in 16% of GC samples.

#### 3.3. Association between co-infection status and age

A significant association between age and co-infection was observed. Fig. 1 shows that patients who had more than 1 infection were affected with GC at a significantly early age than those with no or 1 infection \( (P\text{-value} = 0.004) \).

#### 3.4. Association between infections status and clinicopathological features

The association between the infection status of GC patients and their clinicopathological characteristics is presented in Table 2. Individual Epstein-Barr virus (EBV) infection was observed in (40%) of GC cases. In addition, the frequency of \( H. pylori \) infection was significantly different between intestinal and diffuse gastric cancer [15% versus 85%; \( <0.05 \)]. The prevalence of individual \( H. pylori \) infection was 34% of GC samples, and we found that the presence of \( H. pylori \) in the diffuse type was higher than in the intestinal type. In addition, a significant association was found between \( H. pylori \) infection and differentiation, tumor stage, and lymph node metastasis. While the frequency of co-infection was 16% of GC cases, and no significant association was found between co-infection and gender, stage, and lymph node metastasis.

### 4. Discussion

Emerging evidence has demonstrated an association between cancers and infections by microorganisms, which may play a role in either the initiation of cancer cell growth or its maintenance [29,30]. While much of the gastrointestinal tract represents a favorable environment for microbial life, this is not the case for the stomach, where any microorganism would have to tolerate extremely acidic conditions, antimicrobial compounds, enzymes, and structural barriers [31]. Thus, to colonize the stomach, any pathogen must adapt to an extremely hostile and highly variable environment. In this regard, several studies have been conducted to understand the role of pathogens that infect the human stomach, particularly \( H. pylori \), which is considered the most common cause of gastric carcinogenesis [3–5]. And there is also the main risk factor that is the Epstein-Barr virus (EBV), involved in gastric carcinogenesis [6]. Both pathogens are generally acquired early in life, with approximately 50% of the world’s adult population infected with \( H. pylori \) and 90% with EBV [6,32].

The high prevalence of \( H. pylori \) in gastric tumors has been widely reported around the world [33,34]. A systematic review and meta-analysis showed that \( H. pylori \) eradication therapy was effective in reducing the incidence of GC [35]. In the present study, \( H. pylori \) were positive in 34% of GC samples, and the cagA gene was detected in all \( H. pylori \)-positive tissues, confirming the involvement of the cagA gene in tumor progression. While the exact mechanism by which \( H. pylori \) can induce gastric carcinogenesis has not yet been fully elucidated, it is known that the inflammatory process induced by this bacterium, linked to genetic and epigenetic events in the host, is capable of inducing a cascade of morphological events, including precancerous and malignant transformations (intestinal or diffuse GC) [36,37]. In our study, we found that the presence of \( H. pylori \) in the diffuse type was higher than in the intestinal type, an association that was also confirmed in other studies conducted in locations with high incidence rates of GC [38,39]. In addition, a significant association was found between \( H. pylori \) infection and differentiation, tumor stage, and lymph node metastasis. Regarding the involvement of EBV in the development of GC, this virus is usually present in about 10% of GC cases [18,40]. Our study showed that the incidence of EBV infection in GC patients in our study population was 40%, which is higher than that reported by previous
Regulation of gastric research studies. 
Researchregistry2464. 
Provenance and peer review. 
Not commissioned, externally peer-reviewed.

Ethics approval and consent to participate

The study was approved by the Biomedical Research Ethics Committee of the School of Medicine and Pharmacy of Casablanca (Reference number: No 13/19), Based on the Declaration of Helsinki, and the decision of the Minister of Health No 02/DRC/00. All patients consented to participate in the study according to ethical standards.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author agreement statement

We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We understand that the Corresponding Author is the sole contact for the Editorial process. He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

References

[1] P. Rawla, A. Barsouk, Epidemiology of gastric cancer: global trends, risk factors and prevention, Przeglad Gastroenterol. 14 (1) (2019) 26–38.
[2] F. Bray, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 68 (6) (2018) 394–424.
[3] K.M. Lee, et al., Late reactivation of sonic hedgehog by Helicobacter pylori results in population of gastric epithelial cells that are resistant to apoptotic implication for gastric carcinogenesis, Canc. Lett. 287 (1) (2010) 44–53.
[4] S. Peter, C. Beglinger, Helicobacter pylori and gastric cancer: the causal relationship, Digestion 75 (1) (2007) 25–35.
[5] Schistosomes, liver flukes, Helicobacter pylori, IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 61 (1994) 1–241, 7-14 June 1994: IARC Monogr Eval Carcinog Risks Hum.
[6] M.P. Thompson, R. Kurzrock, Epstein-Barr virus and cancer, Clin. Canc. Res. 10 (3) (2004) 803–821.
[7] D.A. Thorley-Lawson, A. Gross, Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N. Engl. J. Med. 350 (13) (2004) 1328–1337.
[8] L. Fuccio, M.H. Eusebi, F. Barzoli, Gastric cancer, Helicobacter pylori infection and other risk factors, World J. Gastroint. Oncol. 2 (9) (2010) 342–347.
[9] A. Morales-Sanchez, E.M. Fuentes-Panana, Human viruses and cancer, Viruses 6 (10) (2014) 4047–4079.
[10] S. Ishag, L. Nuon, Helicobacter pylori and gastric cancer: a state of the art review, Gastroenterol Hepatol Bed Bench 8 (Suppl 1) (2015) S16–S14.
[11] N. Ohnishi, et al., Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse, Proc. Natl. Acad. Sci. U. S. A. 105 (3) (2008) 1003–1008.
[12] L. Frappier, Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival, Viruses 4 (9) (2012) 1537–1547.
[13] A. Saha, E.S. Robertson, Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis, Future Microbiol. 8 (3) (2013) 323–352.
[14] K.H. Shair, et al., Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model, J. Virol. 86 (9) (2012) 5352–5365.
[15] M. Pakayama, et al., Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach, Lab. Invest. 71 (1) (1994) 73–81.
[16] C.D. Shannon-Lowe, et al., Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells, Proc. Natl. Acad. Sci. U. S. A. 103 (18) (2006) 7065–7070.
[17] S. Singh, H.C. Jha, Status of Epstein-barr virus coinfection with Helicobacter pylori in gastric cancer, J Oncol 3456264 (10) (2017) 21.
F.E. Rihane et al.

[18] Q. Liang, et al., Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer, Gastroenterology 147 (6) (2014) 1350–1362.

[19] X.Z. Chen, et al., Epstein-Barr virus infection and gastric cancer: a systematic review, Medicine 94 (20) (2015), 000000000000792.

[20] S. Imai, et al., Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein, Proc. Natl. Acad. Sci. U. S. A. 91 (19) (1994) 9131–9135.

[21] A.P. Lage, et al., Diagnosis of Helicobacter pylori infection by PCR: comparison with other invasive techniques and detection of cagA gene in gastric biopsy specimens, J. Clin. Microbiol. 33 (10) (1995) 2752–2756.

[22] D. Ortiz-Princz, et al., Helicobacter pylori cagA and vacA genotypes in Cuban and Venezuelan populations, Mem. Inst. Oswaldo Cruz 105 (3) (2010) 331–335.

[23] H. Lu, et al., Putative periodontopathic bacteria and herpesviruses in pregnant women: a case-control study, Sci. Rep. 6 (27976) (2016).

[24] R. Agha, et al., STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156–165.

[25] P. Lauren, The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification, Acta Pathol. Microbiol. Scand. 64 (1965) 31–49.

[26] G. Nardone, A. Rocco, P. Malfertheiner, Review article: helicobacter pylori and molecular events in precancerous gastric lesions, Aliment. Pharmacol. Ther. 20 (3) (2004) 261–270.

[27] M. Watanabe, et al., Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis, Int. J. Canc. 131 (11) (2012) 2632–2642.

[28] S.B. Edge, C.C. Compton, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann. Surg. Oncol. 17 (6) (2010 Jun) 1471–1474, https://doi.org/10.1245/s10434-010-0985-4.

[29] C. Jacqueline, et al., Infections and cancer: the “fifty shades of immunity” hypothesis, BMC Canc. 17 (1) (2017), 17365.

[30] M.M. Azevedo, C. Pina-Vaz, F. Baltazar, Microbes and cancer: friends or foe? Int. J. Mol. Sci. 21 (9) (2020).

[31] M.A. Shah, Gastric cancer: the gastric microbiota - bacterial diversity and implications, Nat. Rev. Gastroenterol. 14 (12) (2017) 692–693.

[32] M.F. Go, Review article: natural history and epidemiology of Helicobacter pylori infection, Aliment. Pharmacol. Ther. 1 (2002) 3–15.

[33] S.A. Batista, et al., Higher number of Helicobacter pylori CagA EPIYA C phosphorylation sites increases the risk of gastric cancer, but not duodenal ulcer, BMC Microbiol. 11 (61) (2011) 1471–2180.

[34] E. Abdi, et al., Helicobacter pylori genotypes determine risk of non-cardia gastric cancer and intestinal- or diffuse-type GC in Ardabil: a very high-risk area in Northwestern Iran, Microb. Pathog. 107 (2017) 287–292.

[35] Y.C. Lee, et al., Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis, Gastroenterology 150 (5) (2016) 1113–1124.

[36] R.M. Peek Jr., M.J. Blaser, Helicobacter pylori pylori and gastrointestinal tract adenocarcinomas, Nat. Rev. Canc. 2 (1) (2002) 28–37.

[37] G. Nardone, D. Compare, Epigenetic alterations due to diet and Helicobacter pylori infection in gastric carcinogenesis, Expet Rev. Gastroenterol. Hepatol. 2 (2) (2008) 243–248.

[38] S.Y. Lee, Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection, Korean J Intern Med 31 (5) (2016) 835–844.

[39] A.N. Etsouki, et al., Gastric cancer and Helicobacter pylori pylori infection in the eastern Libya: a descriptive epidemiological study, Arab J Gastroenterol 13 (2) (2012) 85–88.

[40] C.R. de Souza, et al., Occurrence of Helicobacter pylori and Epstein-Barr virus infection in endoscopic and gastric cancer patients from Northern Brazil, BMC Gastroenterol. 14 (179) (2014) 1479–1799.

[41] K. Takada, Epstein-Barr virus and gastric carcinoma, Mol. Pathol. 53 (5) (2000) 255–261.

[42] D. Salyakina, N.F. Trinoremas, Viral expression associated with gastrointestinal adenocarcinomas in TCGA high-throughput sequencing data, Hum. Genom. 7 (1) (2013) 1479–7364.

[43] A. Abdiras, et al., Epstein-Barr virus associated gastric carcinoma: a report from Iran in the last four decades, Diagn. Pathol. 2 (25) (2007), 1746–1594.

[44] Z. Leila, et al., Detection of Epstein-barr virus and cytomegalovirus in gastric cancers in kerman, Iran, Asian Pac. J. Cancer Prev. APJCP 17 (5) (2016) 2423–2428.

[45] J.H. Lee, et al., Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis, J. Gastroenterol. Hepatol. 24 (3) (2009) 354–365.

[46] C.D. Truong, et al., Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A, J. Exp. Clin. Canc. Res. 28 (1) (2009) 1756–9966.

[47] R.K. Saiki, et al., Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes, Nature 324 (6093) (1986) 9131–9135.

[48] Y.C. Lee, et al., Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis, Gastroenterology 150 (5) (2016) 1113–1124.

[49] R.M. Peek Jr., M.J. Blaser, Helicobacter pylori pylori and gastrointestinal tract adenocarcinomas, Nat. Rev. Canc. 2 (1) (2002) 28–37.

[50] G. Nardone, D. Compare, Epigenetic alterations due to diet and Helicobacter pylori infection in gastric carcinogenesis, Expet Rev. Gastroenterol. Hepatol. 2 (2) (2008) 243–248.

[51] S.Y. Lee, Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection, Korean J Intern Med 31 (5) (2016) 835–844.

[52] A.N. Etsouki, et al., Gastric cancer and Helicobacter pylori pylori infection in the eastern Libya: a descriptive epidemiological study, Arab J Gastroenterol 13 (2) (2012) 85–88.

[53] C.R. de Souza, et al., Occurrence of Helicobacter pylori and Epstein-Barr virus infection in endoscopic and gastric cancer patients from Northern Brazil, BMC Gastroenterol. 14 (179) (2014) 1479–1799.

[54] K. Takada, Epstein-Barr virus and gastric carcinoma, Mol. Pathol. 53 (5) (2000) 255–261.